INTEGRATED BIOPHARMA INC
INBPNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for INBP. That does not mean none is planned.
Get an email about INBP's next catalysts
Track INTEGRATED BIOPHARMA (INBP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
PEG-Interferon a-2b + Ribavirin
Chronic Hepatitis C Infection in HIV-Infected Persons
peginterferon alfa-2b (SCH 54031)
Hepatitis C, Chronic
temozolomide
Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PEG-Interferon a-2b + Ribavirin | Phase 3 | Chronic Hepatitis C Infection in HIV-Infected Persons | - | - |
peginterferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - | - |
temozolomide | Phase 2 | Cancer | - | - |
Frequently asked questions
What is in INTEGRATED BIOPHARMA INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in INTEGRATED BIOPHARMA INC's (INBP) pipeline across Phase 3, Phase 2. Its lead program is PEG-Interferon a-2b + Ribavirin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is INTEGRATED BIOPHARMA INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for INTEGRATED BIOPHARMA INC (INBP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INBP biotech catalysts?→
Add INBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow INTEGRATED BIOPHARMA INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.